

References

I-150

1. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with Daratumumab monotherapy in multiple myeloma. *N Engl J Med*. 2015;373(13):1207-1219.
2. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. *J Immunol*. 2011;186(3):1840-1848.
3. Daratumumab (Darzalex). [prescribing information] Janssen Biotech, Inc., Horsham, PA 19044. 11/2015.
4. Sanchez L, Wang Y, Siegel D, Wang M. Daratumumab: A first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. *Journal of Hematology & Oncology*. 2016;9(1):51. Available from: MEDLINE Complete, Ipswich, MA.
5. Overdijk M, Verploegen S, Parren P, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. *Mabs*. 2015;7(2):311-321. Available from: MEDLINE Complete, Ipswich, MA.
6. Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: A review about the future. *Journal of Hematology & Oncology*. 2016;9(1):52. Available from: MEDLINE Complete, Ipswich, MA.
7. National Comprehensive Cancer Network (NCCN). *NCCN Drugs & Biologics Compendium*. daratumumab (Darzalex). 2016.
8. Truven Health Analytics. Micromedex® DrugDex® Compendium. daratumumab (Darzalex). March 19, 2016. Greenwood Village, CO.
9. US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. daratumumab (Darzalex) drug label. 11/2015.
10. Clinical Pharmacology
11. Rajkumar SV. Multiple myeloma treatment (beyond the basics). In: Kyle RA, ed. Up-To-Date Online 2016
12. Bhatnagar V, Gormley N, Luo L, et al. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy. *The Oncologist*. 2017;22:1347-1353.
13. Sanchez L, Wang Y, Siegel D, & Wang M. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. *Journal of Hematology & Oncology*. 2016;9:51-59.
14. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2016; 375:754-766.

15. National Comprehensive Cancer Network (NCCN). NCCN Multiple Myeloma. Version 3.2018. Accessed February 9, 2018.
16. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. Daratumumab
17. MICROMEDEX®SOLUTIONS Compendia. 2018. Daratumumab. Accessed February 9, 2018.